Table 1.
Baseline patient characteristics and treatments.
| Variables | TP53 mutation− (n = 123) | TP53 mutation+ (n = 18) | Total (n = 141) | Pa |
|---|---|---|---|---|
| Median age (y; range) | 47 (26–75) | 57.5 (41–63) | 48 (41–75) | 0.091b |
| Menopausal status | 0.005c | |||
| Premenopausal | 77 (62.6%) | 5 (27.8%) | 82 (58.2%) | |
| Postmenopausal | 46 (37.4%) | 13 (72.2%) | 59 (41.8%) | |
| Estrogen receptord | 0.652 | |||
| Low | 10 (8.1%) | 2 (11.1%) | 12 (8.5%) | |
| High | 113 (91.9%) | 16 (88.9%) | 129 (91.5%) | |
| Progesterone receptor | 0.475 | |||
| Negative | 17 (13.8%) | 4 (22.2%) | 21 (14.9%) | |
| Positive | 106 (86.2%) | 14 (77.8%) | 120 (85.1%) | |
| T stage | 0.021c | |||
| 1 | 70 (56.9%) | 5 (27.8%) | 75 (53.2%) | |
| 2 or 3 | 53 (43.1%) | 13 (72.2%) | 66 (46.8%) | |
| N stage | 0.773 | |||
| 0 | 93 (75.6%) | 13 (72.2%) | 106 (75.2%) | |
| 1 or 2 | 30 (24.4%) | 5 (27.8%) | 35 (24.8%) | |
| Histologic grade | 0.002 | |||
| 1 or 2 | 111 (91.0%) | 11 (61.1%) | 122 (87.1%) | |
| 3 | 11 (9.0%) | 7 (38.9%) | 18 (12.9%) | |
| Nuclear grade | 0.329 | |||
| 1 or 2 | 101 (82.8%) | 13 (72.2%) | 114 (81.4%) | |
| 3 | 21 (17.2%) | 5 (27.8%) | 26 (18.6%) | |
| LVIe | 0.018 | |||
| Negative | 96 (78.0%) | 9 (50.0%) | 105 (74.5%) | |
| Positive | 27 (22%) | 9 (50.0%) | 36 (25.5%) | |
| Ki-67 | <0.001 | |||
| ≤ 20 | 119 (96.7%) | 12 (66.7%) | 131 (92.9%) | |
| < 20 | 4 (3.3%) | 6 (33.3%) | 10 (7.1%) | |
| Chemotherapy | <0.001 | |||
| No | 99 (80.5%) | 5 (27.8%) | 104 (73.8%) | |
| Yes | 24 (19.5%) | 13 (72.2%) | 37 (26.2%) | |
| Endocrine therapy | 0.117 | |||
| Tamoxifen | 72 (58.5%) | 6 (33.3%) | 78 (55.3%) | |
| AI | 50 (40.7%) | 12 (66.7%) | 62 (44.0%) | |
| Fulvestrant | 1 (0.8%) | 0 (0.0%) | 1 (0.7%) | |
| Radiotherapy | 0.296c | |||
| No | 50 (40.7%) | 5 (27.8%) | 55 (39.0%) | |
| Yes | 73 (59.3%) | 13 (72.2%) | 86 (61.0%) |
aFisher exact test.
bMann–Whitney U test.
Cχ2 test.
dHigh, Allred score 5–8; Low, Allred score 2–4.
eLymphovascular invasion.